IRE1 and proteasome inhibition with STF-083010 and ixazomib, respectively, in KMS11, RPMI-8226, and primary MM cells, and the combination of the above, have pinpointed the therapeutic aspect of UPR mechanism suppression. Here, ERN1 is linked to Miyoshi myopathy.